Current partner codePEPTIDESDE
NCT06916091·Phase 1·INTERVENTIONAL

A Study of Eloralintide (LY3841136) in Chinese Participants With Obesity or Overweight

Status

Completed

Phase

Phase 1

Enrollment

30

Locations

1

Results

Not posted

Publications

0

Study summary

What the protocol is testing.

The purpose of this study is to evaluate how well Eloralintide (LY3841136) is tolerated and what side effects may occur in overweight and obese Chinese participants. The study drug will be administered subcutaneously (SC) (under the skin). Blood tests will be performed to check how much Eloralintide gets into the bloodstream and how long it takes the body to eliminate it. The study will last approximately 10 weeks excluding a screening period.

Interventions

Treatment arms and agents.

DRUG

Eloralintide

Administered subcutaneously (SC)

DRUG

Placebo

Administered SC

Timeline

From registration to results.

  1. First posted

    Apr 8, 2025

  2. Study start

    Apr 21, 2025

  3. Primary completion

    Sep 9, 2025

  4. Study completion

    Sep 9, 2025

  5. Results posted

    Not reported

  6. Registry updated

    Nov 19, 2025

Outcomes

What the study measures.

Primary outcomes

Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

Time frame · Baseline to Study Completion (Up to 10 Weeks)

A summary of TEAEs and SAEs regardless of causality, will be reported in the Reported Adverse Events module

Secondary outcomes

Pharmacokinetics (PK): Maximum Concentration (Cmax) of Eloralintide

Time frame · Baseline to Study Completion (Up to 10 Weeks)

PK:Cmax of Eloralintide

PK: Area Under the Concentration Versus Time Curve (AUC) of Eloralintide

Time frame · Baseline to Study Completion (Up to 10 Weeks)

PK: AUC of Eloralintide

Eligibility

Who can take part.

Minimum age
21 Years
Maximum age
65 Years
Sex
ALL
Healthy volunteers
No

Inclusion Criteria: * Chinese participants. To qualify as Chinese, all 4 of the participant's biological grandparents must be of exclusive Chinese descent and born in China * Have had a stable body weight for 3 months prior to screening. Participants with body weight change of less than 5% will be allowed * Have not modified diet or adopted any nutritional lifestyle modification for 3 months before randomization * Have clinical laboratory test results within a normal range for the population or investigative site at screening and lead-in, or results with acceptable deviations that are judged to be not clinically significant by the investigator * Have a body mass index (BMI) within the range 27 to 40 kilogram per square meter (kg/m²) Exclusion Criteria: * Are pregnant, or intend to become pregnant or to breastfeed during the study * Have known allergies to related compounds of eloralintide * Have any of the following abnormal blood pressure (BP) and/or pulse rate at screening, constituting a risk when taking the investigational product with minor deviations judged to be acceptable by the investigator: * Supine BP \> 160/90 millimeter mercury (mmHg) * Supine pulse rate \< 50 or \> 100 beats per minute (bpm) * Orthostatic hypotension * Have significant previous or current history of comorbidities capable of significantly altering the absorption, metabolism, or elimination of drugs * Regularly use known drugs of abuse and/or show positive findings on drug screening that are not consistent with the medical history or concomitant medication history * Have donated blood of more than 450 mL within the previous 3 months of study screening, or intend to donate blood during the course of the study * Have a history of chronic medical conditions involving the heart, liver, or kidneys * Have a medical history or current evidence of clinically significant cardiac condition

Study locations

1 registered sites.

Singapore. Showing up to 24 locations stored in the fast local snapshot.

Lilly Centre for Clinical Pharmacology

Singapore, Singapore

Publications

Results and literature.

No PMID-linked publications were present in this registry snapshot.

Primary links

Continue at the source.

Related trials

More studies on Eloralintide.

Related PeptideStat pages

Put the record in context.

Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.